{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:36:46Z","timestamp":1767685006949,"version":"3.48.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-06171-6","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:32:26Z","timestamp":1767684746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Persistent lymph node uptake on [18\u00a0F]-FDG PET-CT after neoadjuvant chemotherapy: a major predictive factor of disease-free survival in MIBC"],"prefix":"10.1007","volume":"44","author":[{"given":"Maxime","family":"Pattou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e9goire","family":"Robert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Gouhizoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Gu\u00e9na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abderrahmane","family":"Khaddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samy","family":"Mebroukine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaelle","family":"Margue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Gross-Goupil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Lefort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9ment","family":"Morgat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Bladou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9ment","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"6171_CR1","doi-asserted-by":"publisher","unstructured":"Wagner J et al (2022) Both radiographical and pathological lymph node statuses are independent predictors for survival following neoadjuvant chemotherapy and radical cystectomy for cT3\/4 or cN\u2009+\u2009bladder cancer, World J Urol, vol. 41, no. 1, pp. 101\u2013107, Oct. https:\/\/doi.org\/10.1007\/s00345-022-04187-w","DOI":"10.1007\/s00345-022-04187-w"},{"key":"6171_CR2","doi-asserted-by":"publisher","unstructured":"Horn T et al (2015) Clinical prognosticators of survival in patients with urothelial carcinoma of the bladder and lymph node metastases after cystectomy with curative intent, World J Urol, vol. 33, no. 6, pp. 813\u2013819, Jun. https:\/\/doi.org\/10.1007\/s00345-014-1355-9","DOI":"10.1007\/s00345-014-1355-9"},{"key":"6171_CR3","doi-asserted-by":"publisher","unstructured":"Amin MB et al (2017) The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u2018personalized\u2019 approach to cancer staging, CA A Cancer J Clinicians, vol. 67, no. 2, pp. 93\u201399, Mar. https:\/\/doi.org\/10.3322\/caac.21388","DOI":"10.3322\/caac.21388"},{"key":"6171_CR4","doi-asserted-by":"publisher","unstructured":"Crozier J et al (2019) Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis, World J Urol, vol. 37, no. 4, pp. 667\u2013690, Apr. https:\/\/doi.org\/10.1007\/s00345-018-2439-8","DOI":"10.1007\/s00345-018-2439-8"},{"key":"6171_CR5","doi-asserted-by":"publisher","unstructured":"Barker SJ et al (Nov. 2024) ACR Appropriateness Criteria\u00ae Pretreatment Staging of Urothelial Cancer: 2024 Update. J Am Coll Radiol 21(11):S464\u2013S489. https:\/\/doi.org\/10.1016\/j.jacr.2024.08.022","DOI":"10.1016\/j.jacr.2024.08.022"},{"key":"6171_CR6","doi-asserted-by":"publisher","unstructured":"Soubra A et al (Sep. 2016) The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis. World J Urol 34(9):1229\u20131237. https:\/\/doi.org\/10.1007\/s00345-016-1772-z","DOI":"10.1007\/s00345-016-1772-z"},{"key":"6171_CR7","doi-asserted-by":"publisher","unstructured":"Voskuilen CS et al (Jun. 2022) Staging 18F-fluorodeoxyglucose positron emission tomography\/Computed tomography changes treatment recommendation in invasive bladder cancer. Eur Urol Oncol 5(3):366\u2013369. https:\/\/doi.org\/10.1016\/j.euo.2021.01.005","DOI":"10.1016\/j.euo.2021.01.005"},{"key":"6171_CR8","doi-asserted-by":"publisher","unstructured":"Apolo AB et al (2010) Sep., Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography\/Computed Tomography in Bladder Cancer, JCO, vol. 28, no. 25, pp. 3973\u20133978. https:\/\/doi.org\/10.1200\/JCO.2010.28.7052","DOI":"10.1200\/JCO.2010.28.7052"},{"key":"6171_CR9","doi-asserted-by":"publisher","unstructured":"Roumigui\u00e9 M et al (Nov. 2024) Recommandations fran\u00e7aises du Comit\u00e9 de canc\u00e9rologie de l\u2019AFU \u2013 Actualisation 2024\u20132026: tumeurs de La Vessie infiltrant Le muscle (TVIM). Progr\u00e8s En Urologie - FMC 34(7):F296\u2013F312. https:\/\/doi.org\/10.1016\/j.fpurol.2024.07.211","DOI":"10.1016\/j.fpurol.2024.07.211"},{"key":"6171_CR10","doi-asserted-by":"publisher","unstructured":"Van Der Heijden AG et al (May 2025) European association of urology guidelines on Muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines. Eur Urol 87(5):582\u2013600. https:\/\/doi.org\/10.1016\/j.eururo.2025.02.019","DOI":"10.1016\/j.eururo.2025.02.019"},{"key":"6171_CR11","doi-asserted-by":"publisher","unstructured":"Kibel AS et al (2009) Sep., Prospective Study of [18 F]Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography for Staging of Muscle-Invasive Bladder Carcinoma, JCO, vol. 27, no. 26, pp. 4314\u20134320. https:\/\/doi.org\/10.1200\/JCO.2008.20.6722","DOI":"10.1200\/JCO.2008.20.6722"},{"key":"6171_CR12","doi-asserted-by":"publisher","unstructured":"Abrahamsson J et al (2022) Complete metabolic response with [18 F]fluorodeoxyglucose-positron emission tomography\/computed tomography predicts survival following induction chemotherapy and radical cystectomy in clinically lymph node positive bladder cancer, BJU International, vol. 129, no. 2, pp. 174\u2013181, Feb. https:\/\/doi.org\/10.1111\/bju.15374","DOI":"10.1111\/bju.15374"},{"key":"6171_CR13","doi-asserted-by":"publisher","unstructured":"Eisenhauer EA et al (Jan. 2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"6171_CR14","doi-asserted-by":"publisher","unstructured":"Boellaard R et al (Feb. 2015) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42(2):328\u2013354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x","DOI":"10.1007\/s00259-014-2961-x"},{"key":"6171_CR15","doi-asserted-by":"publisher","unstructured":"Pichler R et al (Jun. 2017) Pelvic lymph node staging by combined 18F-FDG-PET\/CT imaging in bladder cancer prior to radical cystectomy. Clin Genitourin Cancer 15(3):e387\u2013e395. https:\/\/doi.org\/10.1016\/j.clgc.2016.08.009","DOI":"10.1016\/j.clgc.2016.08.009"},{"key":"6171_CR16","doi-asserted-by":"publisher","unstructured":"Vind-Kezunovic S, Bouchelouche K, Ipsen P, H\u00f8yer S, Bell C, Bjerggaard Jensen J (2019) Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and 18F-fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography: Results from a High-volume Centre Including Long-term Follow-up, European Urology Focus, vol. 5, no. 1, pp. 90\u201396, Jan. https:\/\/doi.org\/10.1016\/j.euf.2017.06.005","DOI":"10.1016\/j.euf.2017.06.005"},{"key":"6171_CR17","doi-asserted-by":"publisher","unstructured":"Lerner SP et al (2024) Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer, N Engl J Med, vol. 391, no. 13, pp. 1206\u20131216, Oct. https:\/\/doi.org\/10.1056\/NEJMoa2401497","DOI":"10.1056\/NEJMoa2401497"},{"key":"6171_CR18","doi-asserted-by":"publisher","unstructured":"Assel M et al (Mar. 2019) Guidelines for reporting of statistics for clinical research in urology. Eur Urol 75(3):358\u2013367. https:\/\/doi.org\/10.1016\/j.eururo.2018.12.014","DOI":"10.1016\/j.eururo.2018.12.014"},{"key":"6171_CR19","doi-asserted-by":"publisher","unstructured":"Lavall\u00e9e LT et al (Oct. 2014) Peri-Operative morbidity associated with radical cystectomy in a multicenter database of community and academic hospitals. PLoS ONE 9(10):e111281. https:\/\/doi.org\/10.1371\/journal.pone.0111281","DOI":"10.1371\/journal.pone.0111281"},{"key":"6171_CR20","doi-asserted-by":"publisher","unstructured":"Powles T et al (2021) Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma, N Engl J Med, vol. 384, no. 12, pp. 1125\u20131135, Mar. https:\/\/doi.org\/10.1056\/NEJMoa2035807","DOI":"10.1056\/NEJMoa2035807"},{"key":"6171_CR21","doi-asserted-by":"publisher","unstructured":"Bellmunt J et al (2017) Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma, N Engl J Med, vol. 376, no. 11, pp. 1015\u20131026, Mar. https:\/\/doi.org\/10.1056\/NEJMoa1613683","DOI":"10.1056\/NEJMoa1613683"},{"key":"6171_CR22","doi-asserted-by":"publisher","unstructured":"Powles T et al (2024) Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer, N Engl J Med, vol. 391, no. 19, pp. 1773\u20131786, Nov. https:\/\/doi.org\/10.1056\/nejmoa2408154","DOI":"10.1056\/nejmoa2408154"},{"key":"6171_CR23","doi-asserted-by":"publisher","unstructured":"Bajorin DF et al (2021) Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma, N Engl J Med, vol. 384, no. 22, pp. 2102\u20132114, Jun. https:\/\/doi.org\/10.1056\/nejmoa2034442","DOI":"10.1056\/nejmoa2034442"},{"key":"6171_CR24","doi-asserted-by":"publisher","unstructured":"Katsimperis S et al (1908) Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: Implications for Prognosis and Treatment Personalization, Cancers, vol. 17, no. 12, p. Jun. 2025. https:\/\/doi.org\/10.3390\/cancers17121908","DOI":"10.3390\/cancers17121908"},{"key":"6171_CR25","doi-asserted-by":"publisher","unstructured":"Christensen E et al (2023) Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer, Clinical Cancer Research, vol. 29, no. 8, pp. 1582\u20131591, Apr. https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-3250","DOI":"10.1158\/1078-0432.ccr-22-3250"},{"key":"6171_CR26","doi-asserted-by":"publisher","unstructured":"Longoni M et al (2024) Use of 18F-fluoro\u20102\u2010deoxy\u2010 d \u2010glucose (18F\u2010FDG) PET \/ CT for lymph node assessment before radical cystectomy in bladder cancer patients, BJU International, vol. 134, no. 4, pp. 636\u2013643, Oct. https:\/\/doi.org\/10.1111\/bju.16363","DOI":"10.1111\/bju.16363"},{"key":"6171_CR27","doi-asserted-by":"publisher","unstructured":"Pfister C et al (2021) Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG\/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses, European Urology, vol. 79, no. 2, pp. 214\u2013221, Feb. https:\/\/doi.org\/10.1016\/j.eururo.2020.08.024","DOI":"10.1016\/j.eururo.2020.08.024"},{"key":"6171_CR28","doi-asserted-by":"publisher","unstructured":"Girard A et al (2019) Integrated analysis of 18F-FDG PET\/CT improves preoperative lymph node staging for patients with invasive bladder cancer, Eur Radiol, vol. 29, no. 8, pp. 4286\u20134293, Aug. https:\/\/doi.org\/10.1007\/s00330-018-5959-0","DOI":"10.1007\/s00330-018-5959-0"},{"key":"6171_CR29","doi-asserted-by":"publisher","unstructured":"De Angelis M et al (2025) Neoadjuvant chemotherapy before radical cystectomy in patients with organ-confined and non-organ-confined urothelial carcinoma, Urologic Oncology: Seminars and Original Investigations, vol. 43, no. 1, p. 62.e1-62.e6, Jan. https:\/\/doi.org\/10.1016\/j.urolonc.2024.09.015","DOI":"10.1016\/j.urolonc.2024.09.015"},{"key":"6171_CR30","doi-asserted-by":"publisher","unstructured":"Fritsche H-M et al (Apr. 2013) Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph Node\u2013positive urothelial carcinoma. Eur Urol 63(4):739\u2013744. https:\/\/doi.org\/10.1016\/j.eururo.2012.09.053","DOI":"10.1016\/j.eururo.2012.09.053"},{"key":"6171_CR31","doi-asserted-by":"publisher","unstructured":"Ko WS, Kim S-J (2023) Predictive Value of 18F-FDG PET\/CT for Assessment of Tumor Response to Neoadjuvant Chemotherapy in Bladder Cancer, Clin Nucl Med, vol. 48, no. 7, pp. 574\u2013580, Jul. https:\/\/doi.org\/10.1097\/RLU.0000000000004639","DOI":"10.1097\/RLU.0000000000004639"},{"key":"6171_CR32","doi-asserted-by":"publisher","unstructured":"De Angelis M et al (2025) Race\/Ethnicity Affects Access and Survival Differences After Neoadjuvant or Adjuvant Chemotherapy at Radical Cystectomy in Urothelial Carcinoma Patients, J. Racial and Ethnic Health Disparities, vol. 12, no. 5, pp. 3284\u20133293, Oct. https:\/\/doi.org\/10.1007\/s40615-024-02131-9","DOI":"10.1007\/s40615-024-02131-9"},{"key":"6171_CR33","doi-asserted-by":"publisher","unstructured":"Verghote F et al (Dec. 2021) Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial. BMC Cancer 21(1):1113. https:\/\/doi.org\/10.1186\/s12885-021-08861-x","DOI":"10.1186\/s12885-021-08861-x"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06171-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-06171-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06171-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T07:32:34Z","timestamp":1767684754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-06171-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6171"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-06171-6","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study involved human participants and did not include any experiments on animals. All procedures were conducted in accordance with the ethical standards of the responsible institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments. The study protocol and database were approved by the local ethic committee (CER-BDX 2025-229). All patients received oral and written information and provided consent for data collection and analysis","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All patients received oral and written information and provided consent for data collection and analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"77"}}